|
 |
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright ©ERS Journals Ltd 2007
Statin use is associated with reduced mortality in COPD
Dept of Medicine and Faculty Division, Akershus University Hospital, Lørenskog, Norway.
CORRESPONDENCE: V. Søyseth, Dept of Medicine and Faculty Division, Akershus University Hospital, N-1478-Lørenskog, Norway. Fax: 47 67902125. E-mail: vidar.soyseth{at}medisin.uio.no
Keywords: Chronic obstructive pulmonary disease exacerbation, inhaled corticosteroids, mortality, observational study, statin
Received: August 14, 2006
Accepted October 11, 2006
Patients with chronic obstructive pulmonary disease (COPD) have an increased risk of ischaemic heart disease (IHD). Statins reduce mortality and morbidity in IHD. It has been hypothesised that statin treatment is associated with reduced long-term mortality in patients with COPD.
Using a retrospective cohort design, 854 consecutive patients (mean age 70.8 yrs; 51.5% female) with a diagnosis of COPD exacerbation were included in the study at discharge from a Norwegian teaching hospital.
Median follow-up was 1.9 yrs, during which 333 patients died. The crude mortality rate per 1,000 person-yrs was 110 in patients treated with statins, and 191 in patients not treated with statins. After adjustment for sex, age, smoking, pulmonary function and comorbidities, the hazard ratio (HR) for statin users versus statin nonusers was 0.57 (95% confidence interval 0.38–0.87). When subdividing statin users and statin nonusers into groups according to concomitant treatment with inhaled corticosteroids (ICS) the following HRs were found: 0.75 (0.58–0.98) for ICS only; 0.69 (0.36–1.3) for statins only; and 0.39 (0.22–0.67) for the combined treatment with statin and ICS compared with no such treatment.
Treatment with statins was associated with improved survival after chronic obstructive pulmonary disease exacerbation, while inhaled corticosteroids appeared to increase the survival benefit associated with statin use.
This article has been cited by other articles:
|
|
 |
|
  A. A. Zeki, L. Franzi, J. Last, and N. J. Kenyon Simvastatin Inhibits Airway Hyperreactivity: Implications for the Mevalonate Pathway and Beyond Am. J. Respir. Crit. Care Med., October 15, 2009; 180(8): 731 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Churg and J. L. Wright Testing Drugs in Animal Models of Cigarette Smoke-induced Chronic Obstructive Pulmonary Disease Proceedings of the ATS, September 15, 2009; 6(6): 550 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Janda, K. Park, J. M. FitzGerald, M. Etminan, and J. Swiston Statins in COPD: A Systematic Review Chest, September 1, 2009; 136(3): 734 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R P Young, R Hopkins, and T E Eaton Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence Postgrad. Med. J., August 1, 2009; 85(1006): 414 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Richens, D. J. Linderman, S. A. Horstmann, C. Lambert, Y.-Q. Xiao, R. L. Keith, D. M. Boe, K. Morimoto, R. P. Bowler, B. J. Day, et al. Cigarette Smoke Impairs Clearance of Apoptotic Cells through Oxidant-dependent Activation of RhoA Am. J. Respir. Crit. Care Med., June 1, 2009; 179(11): 1011 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sakamoto, S. Hayashi, H. Mukae, R. Vincent, J. C. Hogg, and S. F. van Eeden Effect of Atorvastatin on PM10-induced Cytokine Production by Human Alveolar Macrophages and Bronchial Epithelial Cells International Journal of Toxicology, January 1, 2009; 28(1): 17 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gerhardsson de Verdier The Big Three Concept: A Way to Tackle the Health Care Crisis? Proceedings of the ATS, December 1, 2008; 5(8): 800 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. MacNee, J. Maclay, and D. McAllister Cardiovascular Injury and Repair in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, December 1, 2008; 5(8): 824 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. I. Rennard Lessons from Multidisciplinary Cross-Fertilization: Chronic Obstructive Pulmonary Disease, Lung Cancer, and Heart Disease Proceedings of the ATS, December 1, 2008; 5(8): 865 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Gross Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation Mayo Clin. Proc., November 1, 2008; 83(11): 1241 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Wood and R. A. Stockley Editorial: Unifying the genetics, co-morbidities and management of COPD Therapeutic Advances in Respiratory Disease, June 1, 2008; 2(3): 113 - 117. [PDF]
|
|
|
|
 |
|
 E Crisafulli, S Costi, F Luppi, G Cirelli, C Cilione, O Coletti, L M Fabbri, and E M Clini Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation Thorax, June 1, 2008; 63(6): 487 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Albert and P. M. A. Calverley Drugs (including oxygen) in severe COPD Eur. Respir. J., May 1, 2008; 31(5): 1114 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. MacNee Update in Chronic Obstructive Pulmonary Disease 2007 Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 820 - 829. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Churg, M. Cosio, and J. L. Wright Mechanisms of cigarette smoke-induced COPD: insights from animal models Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L612 - L631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Brekke, T. Omland, S. H. Holmedal, P. Smith, and V. Soyseth Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation Eur. Respir. J., March 1, 2008; 31(3): 563 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Murphy, I. A. Forrest, P. A. Corris, G. E. Johnson, T. Small, D. Jones, A. J. Fisher, J. J. Egan, T. E. Cawston, C. Ward, et al. Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients Am J Physiol Lung Cell Mol Physiol, March 1, 2008; 294(3): L592 - L599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Han, V. V. McLaughlin, G. J. Criner, and F. J. Martinez Pulmonary Diseases and the Heart Circulation, December 18, 2007; 116(25): 2992 - 3005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Alexeeff, A. A. Litonjua, D. Sparrow, P. S. Vokonas, and J. Schwartz Statin Use Reduces Decline in Lung Function: VA Normative Aging Study Am. J. Respir. Crit. Care Med., October 15, 2007; 176(8): 742 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Young, R. Hopkins, and T. E. Eaton Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes Eur. Respir. J., October 1, 2007; 30(4): 616 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Singh Does Regular Physical Activity Reduce Lung Function Decline and COPD Risk among Smokers? Am. J. Respir. Crit. Care Med., August 1, 2007; 176(3): 314 - 314. [Full Text] [PDF]
|
|
|
|
|
|
M. Rudolf COPD and death: what exactly is the relationship? Thorax, May 1, 2007; 62(5): 378 - 379. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |